Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.
暂无分享,去创建一个
[1] W. Wels,et al. Antitumor effect of an HER2‐specific antibody–toxin fusion protein on human prostate cancer cells , 2001, The Prostate.
[2] C. Proud. Peptide-chain elongation in eukaryotes , 1994, Molecular Biology Reports.
[3] J. Rothman,et al. The capacity to retrieve escaped ER proteins extends to the trans-most cisterna of the Golgi stack , 1995, The Journal of cell biology.
[4] I. Pastan,et al. In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma , 2004, Cancer Research.
[5] M. Schroth,et al. Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa. , 1974, Applied microbiology.
[6] M. Moroni,et al. Pseudomonas infections in patients with AIDS and AIDS‐related complex , 1992, Journal of internal medicine.
[7] J. Chang,et al. Expression of 14-3-3delta, cdc2 and cyclin B proteins related to exotoxin A-induced apoptosis in HeLa S3 cells. , 2007, International immunopharmacology.
[8] L. Steinstraesser,et al. Host defense peptides in burns. , 2004, Burns : journal of the International Society for Burn Injuries.
[9] V. Diehl,et al. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. , 1998, International journal of molecular medicine.
[10] R. Read,et al. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. , 1997, Biochemistry.
[11] I. Pastan,et al. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] D. Mckay,et al. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[13] I. Pastan,et al. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] J. Tommassen,et al. Secretion of Elastinolytic Enzymes and Their Propeptides by Pseudomonas aeruginosa , 1998, Journal of bacteriology.
[15] D. Kabat,et al. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[16] I. Pastan,et al. Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers , 2007, Clinical Cancer Research.
[17] N. Dang,et al. Denileukin Diftitox as Novel Targeted Therapy for Lymphoid Malignancies , 2007, Cancer investigation.
[18] R. Bast,et al. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. , 2001, Gynecologic oncology.
[19] Rab9 functions in transport between late endosomes and the trans Golgi network. , 1993, The EMBO journal.
[20] U. Wetterauer,et al. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells , 2006, Cancer Immunology, Immunotherapy.
[21] J. D. White,et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I. Pastan,et al. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Neefjes,et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. , 2000, Immunity.
[24] I. Pastan,et al. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[25] James J. Vincent,et al. Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1 , 2006, The Journal of Immunology.
[26] M. Berger,et al. Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors , 2003, Journal of Neuro-Oncology.
[27] M. Bally,et al. GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa. , 1998, FEMS microbiology reviews.
[28] R. Kreitman,et al. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. , 1997, Biochemistry.
[29] V. Malhotra,et al. Src Regulates Golgi Structure and KDEL Receptor-dependent Retrograde Transport to the Endoplasmic Reticulum* , 2003, Journal of Biological Chemistry.
[30] A. Omori,et al. Molecular Cloning, Sequencing, and Expression of the Gene Encoding Alkaline Ceramidase from Pseudomonas aeruginosa , 1999, The Journal of Biological Chemistry.
[31] G. Maschmeyer,et al. Review of the Incidence and Prognosis of Pseudomonas aeruginosa Infections in Cancer Patients in the 1990s , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[32] W. Wilson,et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Rappuoli,et al. Three conserved consensus sequences identify the NAD‐binding site of ADP‐ribosylating enzymes, expressed by eukaryotes, bacteria and T‐even bacteriophages , 1996, Molecular microbiology.
[34] R. Puri,et al. Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor , 2005, Journal of immunotherapy.
[35] R. Puri,et al. Targeting interleukin-4 receptors for effective pancreatic cancer therapy. , 2002, Cancer research.
[36] P. Friedman,et al. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. , 1993, Cancer research.
[37] G. Schreiber,et al. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. , 1997, Blood.
[38] E. Vitetta. Immunotoxins and vascular leak syndrome. , 2000, Cancer journal.
[39] J. Tommassen,et al. Identification of a Chitin-Binding Protein Secreted by Pseudomonas aeruginosa , 2000, Journal of bacteriology.
[40] P. Koehl,et al. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. , 2001, Journal of molecular biology.
[41] D. Saul,et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. , 2002, Cancer research.
[42] M. Vasil,et al. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. , 1986, The Journal of pediatrics.
[43] I. Pastan,et al. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. , 1995, The Biochemical journal.
[44] H. Cunliffe,et al. Characterization of an Endoprotease (PrpL) Encoded by a PvdS-Regulated Gene in Pseudomonas aeruginosa , 2001, Infection and Immunity.
[45] R. Puri,et al. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. , 2000, Cancer research.
[46] Ø. Fodstad,et al. Downregulation of the antiapoptotic MCL‐1 protein and apoptosis in MA‐11 breast cancer cells induced by an anti‐epidermal growth factor receptor–Pseudomonas exotoxin a immunotoxin , 2004, International journal of cancer.
[47] G. R. Andersen,et al. Stealth and mimicry by deadly bacterial toxins. , 2006, Trends in biochemical sciences.
[48] I. Pastan,et al. Apoptosis induced by Pseudomonas exotoxin: a sensitive and rapid marker for gene delivery in vivo. , 1999, Human gene therapy.
[49] J. Tommassen,et al. Characterization of Pseudomonas aeruginosa Chitinase, a Gradually Secreted Protein , 2001, Journal of bacteriology.
[50] E. Vitetta,et al. Vascular leak syndrome: a side effect of immunotherapy. , 1997, Immunopharmacology.
[51] E. Chen,et al. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[52] W. Wels,et al. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors , 2007, Molecular Cancer Therapeutics.
[53] W. Grizzle,et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] Alain Filloux,et al. A novel type II secretion system in Pseudomonas aeruginosa , 2002, Molecular microbiology.
[55] A. Schwan,et al. Exotoxin A–eEF2 complex structure indicates ADP ribosylation by ribosome mimicry , 2005, Nature.
[56] A. Martínez,et al. Identification of an additional member of the secretin superfamily of proteins in Pseudomonas aeruginosa that is able to function in type II protein secretion , 1998, Molecular microbiology.
[57] D. V. Von Hoff,et al. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. , 1993, The Journal of urology.
[58] I. Pastan,et al. Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.
[59] I. Pastan,et al. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A , 2001, Journal of immunotherapy.
[60] A. Prince,et al. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. , 2007, Current opinion in pharmacology.
[61] A. Plückthun,et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] I. Pastan,et al. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[63] K Nakayama,et al. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. , 1997, The Biochemical journal.
[64] T. Oda,et al. Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin. , 1998, Journal of biochemistry.
[65] R. Pepperkok,et al. The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. , 1999, Journal of cell science.
[66] I. Pastan,et al. Targeted therapy of cancer with recombinant immunotoxins. , 1997, Biochimica et biophysica acta.
[67] I. Pastan,et al. Administration of disulfide‐stabilized Fv‐immunotoxins B1(dsFv)‐PE38 and B3(dsFv)‐PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice , 1995, International journal of cancer.
[68] Sebastian Harder,et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas , 2005, Breast Cancer Research.
[69] H. P. Fell,et al. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[70] R. Puri,et al. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. , 2001, Cancer research.
[71] H. Pelham,et al. Toxin entry: how reversible is the secretory pathway? , 1992, Trends in cell biology.
[72] D. Musher,et al. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[73] M. Vasil,et al. Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa , 1990, Journal of bacteriology.
[74] R. Puri,et al. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] D. Liggitt,et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] T. Kinzy,et al. Dominant-negative mutant phenotypes and the regulation of translation elongation factor 2 levels in yeast , 2005, Nucleic acids research.
[77] B. Azadian,et al. Two Neutropenic Patients with Multiple Resistant Pseudomonas Aeruginosa Septicaemia Treated with Ciprofloxacin , 1987, Journal of the Royal Society of Medicine.
[78] H. Hirschberg,et al. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. , 2004, Journal of neurosurgery.
[79] K. Klimpel,et al. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases , 1995, Infection and immunity.
[80] D. Saul,et al. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells , 2007, Leukemia.
[81] P. Liu,et al. Extracellular toxins of Pseudomonas aeruginosa. , 1974, The Journal of infectious diseases.
[82] V. Diehl,et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETÁ) is a potent immunotoxin against a Hodgkin-derived cell line , 1999, British Journal of Cancer.
[83] I. Pastan,et al. Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin , 1996, Nature Medicine.
[84] P. Linsley,et al. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. , 1997, Journal of immunology.
[85] Y. Reiter. Recombinant immunotoxins in targeted cancer cell therapy. , 2001, Advances in cancer research.
[86] D. Strickland,et al. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. , 1992, The Journal of biological chemistry.
[87] R K Jain,et al. Delivery of Molecular Medicine to Solid Tumors , 1996, Science.
[88] I. Pastan,et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[89] P. Michl,et al. Bacteria and bacterial toxins as therapeutic agents for solid tumors. , 2004, Current cancer drug targets.
[90] B. Groner,et al. Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2 , 2003, Breast Cancer Research and Treatment.
[91] I. Pastan,et al. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. , 1990, The Journal of biological chemistry.
[92] I. Pastan,et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[93] S. Létoffé,et al. Isolation and characterization of an extracellular haem‐binding protein from Pseudomonas aeruginosa that shares function and sequence similarities with the Serratia marcescens HasA haemophore , 1998, Molecular microbiology.
[94] I. Pastan,et al. Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in vitro and in vivo , 2000, Molecular medicine.
[95] A. Filloux,et al. The AprX protein of Pseudomonas aeruginosa: a new substrate for the Apr type I secretion system. , 2001, Gene.
[96] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.
[97] G. Cornelis,et al. Assembly and function of type III secretory systems. , 2000, Annual review of microbiology.
[98] I. Pastan,et al. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma , 1994 .
[99] I. Pastan,et al. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. , 1993, Journal of neurosurgery.
[100] I. Pastan,et al. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. , 2000, International journal of oncology.
[101] I. Pastan,et al. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). , 1991, Cancer research.
[102] Merrill Ar,et al. Investigation into the Catalytic Role for the Tryptophan Residues within Domain III of Pseudomonas aeruginosa Exotoxin A , 1996 .
[103] B. Groner,et al. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.
[104] S. Leppla,et al. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases , 1994, Infection and immunity.
[105] Russo,et al. Phase I Clinical Study of the Recombinant Oncotoxin TP4O in Superficial Bladder Cancer , 2005 .
[106] Ludger Johannes,et al. Rab6 Coordinates a Novel Golgi to ER Retrograde Transport Pathway in Live Cells , 1999, The Journal of cell biology.
[107] I. Pastan,et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[108] A. Issekutz,et al. Pseudomonas aeruginosa Exotoxin A Induces Human Mast Cell Apoptosis by a Caspase-8 and -3-dependent Mechanism* , 2004, Journal of Biological Chemistry.
[109] J. Rizo,et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[110] J. Murray,et al. Internalized Pseudomonas Exotoxin A can Exploit Multiple Pathways to Reach the Endoplasmic Reticulum , 2006, Traffic.
[111] I. Pastan,et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[112] I. Pastan,et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[113] Anthony Asher,et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma , 2003, Journal of Neuro-Oncology.
[114] A. Gillespie,et al. Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts. , 1999, The Journal of urology.
[115] Wilbert Bitter,et al. Secretins of Pseudomonas aeruginosa: large holes in the outer membrane , 2003, Archives of Microbiology.
[116] S. Litvinov,et al. The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.
[117] I. Pastan,et al. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. , 1992, The Journal of biological chemistry.
[118] H. Pelham,et al. pH-dependent binding of KDEL to its receptor in vitro. , 1993, The Journal of biological chemistry.
[119] A. R. Merrill,et al. Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A. , 2004, The Biochemical journal.
[120] U. Wetterauer,et al. Anti‐PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice , 2008, The Prostate.
[121] I. Pastan,et al. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. , 1989, The Journal of biological chemistry.
[122] I. Pastan,et al. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[123] M. Lohoff,et al. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. , 1998, Journal of immunology.
[124] D. Kabat,et al. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo , 1977, Infection and immunity.
[125] I. Pastan,et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein , 2002, British Journal of Cancer.